Boshutai®Acarbose Tablets
Boshutai® , the first anti-diabetic drug developed by Uni-Bio Science Group, received market approval from the China NMPA in November 2020. The product was subsequently included in the centralized procurement list of the 17-province alliance led by Henan in 2024
As an adjunct to dietary control for:
(1) Type 2 diabetes
(2) Reducing postprandial blood glucose in individuals with impaired glucose tolerance
50mg；100mg
Mechanism of Action
Acarbose is a biosynthetic pseudotetrasaccharide. Animal studies demonstrate that it inhibits α-glucosidase activity located in the brush border of intestinal wall cells, thereby delaying the breakdown of polysaccharides, oligosaccharides, and disaccharides. This mechanism slows glucose release and absorption from carbohydrates, attenuates postprandial blood glucose elevation, and reduces average blood glucose levels.
Product Advantages
-
Effectively lowers postprandial blood glucose and supports long-term glycemic control -
Reduces glycemic fluctuations and associated risks -
Delays progression from IGT to type 2 diabetes -
Potential cardiovascular benefits -
Recommended by multiple clinical guidelines
More Products
-
Pinup®Voriconazole TabletsPinup® represent a broad-spectrum triazole antifungal agent indicated for the treatment of the following fungal infections in adult and pediatric patients aged 2 years and older
-
Boshutai®Acarbose TabletsAs an adjunct to dietary control for: (1) Type 2 diabetes (2) Reducing postprandial blood glucose in individuals with impaired glucose tolerance
-
金因康®Diquafosol Sodium Eye Drops金因康® is indicated for patients diagnosed with dry eye accompanied by keratoconjunctival epithelial damage associated with tear deficiency.
